Metfendrazine
Appearance
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by DMacks (talk | contribs) at 15:42, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 15:42, 22 June 2020 by DMacks (talk | contribs) (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB))
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H16N2 |
Molar mass | 164.252 g·mol−1 |
Metfendrazine (HM-11, MO-482), also known as methphendrazine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class.[1][2] It was investigated as an antidepressant, but was never marketed.
See also
References
- ^ Miquel, J.; Mijan, C. D. (1962). "Metfendrazine, a new inhibitor of monoamine oxidase". Arch. Inst. Farmacol. Exp. (Madrid). 14: 47–59.
- ^ Kothari NJ, Saunders JC, Kline NS, Griffen JA (October 1960). "A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics". The American Journal of Psychiatry. 117: 358–60. doi:10.1176/ajp.117.4.358. PMID 13753478.
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
|
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |